Articles tagged with Drug Discovery
Researchers discovered new structural details of an angiotensin II receptor called AT2, which could be a target for new medicines. The information uncovered could give drug developers a new path for compounds that combat pain and inflammation or promote tissue regeneration.
Scientists have discovered a synergistic effect between an anticancer and an antirheumatic drug, improving the former's ability to kill off cancer cells. The combination works by interacting with the cell's DNA, disrupting normal function and causing cell death.
A team of scientists from Kyoto University has developed a simpler approach to drug discovery using decision trees, achieving high predictive ability with reduced data sets. The new method could lead to significant cost savings in the drug development process.
Researchers have created a precise atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be changed to make it more effective. The study provides a route to develop new treatments with fewer resources and potentially reduced side effects.
Scientists discovered that resveratrol preserves neuromuscular synapses and muscle fibers in aging mice, mirroring the effects of a low-calorie diet and exercise. Metformin also showed neuroprotective qualities, slowing muscle fiber aging without affecting neuromuscular junctions.
A Penn study found that a high-fat diet causes epigenetic changes in fat cells, leading to obesity and type 2 diabetes. The research also identified a genetic defect in the Ucp1 gene that contributes to obesity, which can be overcome with treatment.
McMaster researchers have discovered a new combination therapy that effectively treats the world's worst infectious diseases, including superbugs resistant to all known antibiotics. The treatment targets Gram-negative bacteria with an intrinsically impenetrable outer shell, making infections deadly in hospital settings.
Researchers at Georgia Institute of Technology have developed triboelectric nanogenerators to charge molecules in mass spectrometers, dramatically boosting sensitivity and allowing for smaller sample volumes. The technology enables controlled ionization and eliminates waste, opening new avenues for scientific applications.
Researchers have discovered a new way to identify and test new drugs using differential mobility spectrometry (DMS), which analyzes drug molecules based on their response to an electrical field. This technique can measure drug properties in seconds, allowing for high-throughput testing of hundreds or thousands of drugs.
Researchers have identified B0AT1 inhibitors as a potential replacement for gastric bypass surgery in treating obesity and related disorders. These compounds, including benztropine, could replicate the effects of gastric bypass by reducing nutrient absorption, offering a new treatment option.
A Virginia Tech research team has received a $431,126 NIH grant to improve the malaria compound MMV008138. The team aims to create more potent versions of the drug targeting the parasite's ability to produce isopentenyl pyrophosphate.
The Harrington Discovery Institute has selected three 2016 partnership scholars to support groundbreaking research in Alzheimer's disease and blindness. The scholars will receive funding and expert pharmaceutical guidance to advance their discoveries into new medicines.
Researchers at Michigan State University have discovered a chemical compound that can stop the spread of melanoma cells by up to 90 percent. The compound targets a gene's ability to produce RNA molecules and proteins in melanoma tumors, effectively shutting down the disease's progression.
A team of Vanderbilt researchers has cleared a major hurdle in their quest to develop an Alzheimer's treatment, with the FDA approving its first human trial. The investigational drug aims to target major pathologies of the disease and selectively activate a key receptor in the brain.
Scientists at InSilico Medicine developed a proof-of-concept AI model using Generative Adversarial Autoencoders (AAEs) to generate molecular fingerprints of cancer-killing molecules. The study demonstrates the potential for AI to accelerate pharmaceutical R&D and improve clinical trial success rates.
Researchers developed an efficient process to rapidly discover new 'enediyne natural products' from soil microbes that could be further developed into extremely potent anticancer drugs. The study highlights microbial natural products as abundant sources of new drug leads, saving time and resources compared to traditional approaches.
Researchers discovered that two M1-selective medications reversed memory deficits and extended the lifespan of mice with neurodegenerative disease. The findings support the concept that more specific drugs can be effective in treating cognitive symptoms.
A team of researchers has identified a network of genes in the brain that contribute to epilepsy, and predicts that a known anti-epileptic drug can restore its function. The study's 'network-biology' approach may provide a faster and cheaper way to discover new treatments.
A new study reveals that diabetes drugs' weight loss effects are controlled by multiple brain regions, excluding the hypothalamus. Researchers hope to develop more effective treatments for obesity by understanding how these drugs work in the brain.
IUPUI chemists have developed a new molecular binding technique that can shorten or abridge the human and animal drug discovery and development process. The new method, which uses site-selective C-H arylation of primary aliphatic amines, has potential benefits for both the pharmaceutical industry and patients.
Researchers discover over 31,000 repurposable drug candidates for various diseases, including Parkinson's and tuberculosis. The study uses computational methods to identify shared properties between genes, drugs, and diseases, promising a more efficient and cost-effective approach to pharmaceutical discoveries.
Researchers found a genetic alteration in the DIXDC1 gene that affects brain cell growth and communication in individuals with autism spectrum disorders. This discovery holds promise for identifying new medications targeting core symptoms of autism.
IDRI's TB Discovery Program will focus on developing more effective, cheaper, and faster-acting drugs to combat multi-drug resistant TB strains. The new funding from Eli Lilly will support the screening of over 500,000 compounds in search of potential TB drugs.
A newly identified protein, NTR2, has been discovered that activates drugs like delamanid against leishmaniasis. This finding holds promise for developing more effective treatments for the disease.
Researchers at University of Minnesota and Dow Chemical Company developed a new method for customizing ingredients in oral medications to improve solubility and absorption. The discovery has the potential to lower production costs and advance the development of life-saving drugs.
Researchers at Johns Hopkins Medicine have developed a modified cancer drug that enhances its ability to reach the brain, improving delivery and reducing toxicity. The new compound shows promise in treating brain tumors by targeting tumor metabolism and evading immune cells.
Researchers explore using human pluripotent stem cells to identify cardiotoxicity risks in patients taking chemotherapy agents and other drugs. This approach may boost the number of successful clinical trials for cardiovascular disease treatments.
The article presents a comprehensive overview of in silico drug repurposing methods, highlighting the advantages and disadvantages of various techniques. The authors emphasize the potential of incorporating deep learning approaches into modular workflows, which can accelerate development and reduce costs.
The team created highly uniform arrays of low surface tension functional water-based droplets for biochemical experiments, overcoming current patterning limitations. This non-contact method has potential applications in drug discovery and clinical diagnostics.
Insilico Medicine will present new research data on geroprotectors, small molecules that mimic the young healthy state in old human tissues. The results are a result of a multi-year research program with multiple in silico predictions made using algorithms validated using data from many age-related diseases.
Researchers at the University of Georgia have discovered a new drug that can be administered orally to treat human African trypanosomiasis, a parasitic disease affecting rural communities in sub-Saharan Africa. The study's lead author hopes to accelerate development of new treatments for this complex disease.
Researchers at UNIST have developed a new synthetic method to design and synthesize bioactive compounds and chemical tools for pharmacological studies. This breakthrough improves the scientific basis for drug discovery by understanding biochemical mechanisms for diseases.
A global team of researchers has created and tested a panel of 400 chemical compounds, dubbed the 'Malaria Box', with potential application as therapeutic starting points for diseases like malaria, trypanosomiasis and toxoplasmosis. The collaboration opens new doors for international advances in drug discovery.
Researchers at University of Leeds and Hebei Medical University found that Substance P reduces sensations of pain in peripheral nervous system but triggers pain in central nervous system. This discovery could lead to new methods for pain control with limited side effects.
Researchers from around the world collaborated on an open-source drug-discovery project, identifying compounds to treat malaria, other parasites, and even cancer. The successful trial has sparked over a dozen new drug-development projects, bridging the gap between academia and industry.
Scientists at the University of Sussex are developing new cancer drugs that target DNA damage response pathways to selectively kill cancer cells. These drugs aim to maximize DNA damage or prevent its repair, leading to cancer cell death while minimizing harm to healthy tissues.
Researchers at Thomas Jefferson University have found a new way to keep the heart pumping, which could lead to new drugs for heart disease. By activating the beta2-adrenergic receptor, they can promote the contraction of heart muscle cells and potentially treat heart failure.
Seattle researchers deciphered how tuberculosis bacteria tolerates bedaquiline by silencing regulatory genes or pairing with pretomanid, disrupting tolerance gene networks to improve efficacy. This systems-approach represents a significant advance in the fight against tuberculosis.
Insilico Medicine scientists will present advances in deep learning for biomarker development and drug discovery at the ISFA-Columbia University Actuarial Science Workshop. The workshop aims to integrate deep learning with actuarial science to assess risk in finance, insurance, and other industries.
Fifty NSF-funded biotech companies will exhibit innovative products and processes, including diagnostics and monitoring technologies, drug discovery platforms, and engineering biology innovations. These early-stage companies have the potential to transform the US healthcare system with novel high-tech solutions.
Scientists from Insilico Medicine used deep neural networks to predict therapeutic use of large numbers of drugs from gene expression data, achieving 54.6% accuracy in class prediction. The study also found that many misclassified drugs had dual use, suggesting potential for drug repurposing.
Insilico Medicine presents research on applying deep learning to biomarker development and cosmetics applications at INNOCOS World Beauty Innovation Summit. The company's app RYNKL evaluates anti-aging interventions using machine learning methods, minimizing animal testing.
Researchers have identified a chemical compound eCF506 that effectively blocks breast cancer cell growth, targeting a specific molecule required for tumor progression. The findings suggest eCF506 may be more effective and have fewer side effects than existing drugs, with further studies needed to confirm its potential.
A new database has been developed to connect environmental exposures to human health effects and compare diseases. The Comparative Toxicogenomics Database (CTD) manually curates data from scientific literature on how environmental chemicals interact with genes to affect human health.
A promising discovery has been made in treating and preventing human parainfluenza virus, the second most prevalent cause of acute respiratory tract infection in infants. Researchers have found that combining two existing drugs, Suramin and Relenza, can effectively block the infection.
A team of scientists has identified a possible use for the leukemia treatment drug Imatinib in treating type 2 diabetes. Gleevec was found to lower insulin resistance by controlling PPARγ, reducing the risk of hyperglycemia and obesity.
Saint Louis University researcher Fran Sverdrup is developing a treatment for Facioscapulohumeral Muscular Dystrophy (FSHD), a disease that causes muscle degeneration in 15,000 or more people. Ultragenyx will fund the process of turning SLU's initial discoveries into a drug that could demonstrate proof of concept.
Researchers at U of T Engineering have developed a new way of growing realistic human tissues outside the body, called AngioChip. The technology uses a three-dimensional structure complete with internal blood vessels and can be used to test drugs on lab-grown human tissues, providing a realistic model at a fraction of the cost.
Experts argue that drug discovery should focus on 'validity', predicting results in sick people, rather than industrialization or fashion. Mathematical tools show that small changes in validity can have a bigger effect than running more experiments.
A study published in The Lancet Neurology found that people with Parkinson's who took the oral drug rivastigmine were 45% less likely to fall and steadier when walking. This breakthrough treatment has the potential to improve quality of life for millions worldwide.
InSilico Medicine presents recent advances in applying signaling pathway activation analysis and deep learning to drug discovery and age-related diseases. The company's mission is to extend healthy human longevity through faster and more effective diagnostics and cures.
Researchers have developed a computer model that applies social network analysis techniques to identify new ways of treating cancer. The model maps the interactions between cancer-causing proteins, predicting which ones will be most effectively targeted with drugs.
The Deep Knowledge Life Sciences (DKLS) investment fund will invest in companies with breakthrough technologies, focusing on genetics of age-related diseases, oncology, and regenerative medicine. DKLS will combine AI insights from VITAL with top-level expertise to create analyses and treatments for diseases while de-risking investments.
A team of researchers at UCSF developed ORACLs, a lineage of genetically modified cancer cells that change their appearance when treated with drugs, inspired by face-recognition software. These cells can quickly organize molecules in institutional compound libraries according to their biological function.
Researchers at Griffith University have made a groundbreaking discovery about how bacteria interact with human cells, revealing high-affinity biomolecular interactions between glycans that were previously thought to be weak or non-existent. This finding opens up new avenues for developing vaccines and drugs to block infections.
A team of researchers combined large genomic and proteomic datasets to identify new factors that can be targeted to prevent viruses from spreading. They found 20 previously unrecognized host proteins required for IAV replication, including the pivotal protein UBR4.
The Target Validation Platform provides a single, robust infrastructure that integrates high-level information from key sources of evidence. It enables communities to work together, making the hand-off from basic research to drug discovery smoother, and is expected to grow substantially as it integrates experimental project data.
Researchers at the University of York have developed a new approach to make medicinally important molecules with large rings, called macrocycles. This method allows for their 'growth' from existing rings using ring enlargement reactions, paving the way for the development of new classes of life-saving medicines.
The paper calls for creating a task force to evaluate the classification of aging as a disease in ICD-11. Classifying aging as a disease could help shift the focus from treatment to prevention, attracting more resources to aging research and business cases for pharmaceutical companies.
Scientists at UNC and UCSF create general tool to probe orphan receptor activity, illuminating their roles in behavior. They found a novel probe molecule that can modulate the orphan G protein-coupled receptor 68 (GPR68), which is highly expressed in the brain.